Total Payments
$4,399
2024 Payments
$4,254
Companies
19
Transactions
38
Payment Breakdown by Category
Research$2,435 (55.3%)
Consulting$1,425 (32.4%)
Food & Beverage$539.35 (12.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,435 | 13 | 55.3% |
| Consulting Fee | $1,425 | 1 | 32.4% |
| Food and Beverage | $539.35 | 24 | 12.3% |
Payments by Type
Research
$2,435
13 transactions
General
$1,964
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $2,435 | 13 | $0 (2024) |
| Genentech USA, Inc. | $1,551 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $50.14 | 3 | $0 (2024) |
| UCB, Inc. | $42.24 | 2 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $36.70 | 2 | $0 (2024) |
| Amgen Inc. | $32.20 | 1 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $31.98 | 2 | $0 (2024) |
| CSL Behring | $24.20 | 1 | $0 (2023) |
| Octapharma USA, Inc. | $24.04 | 1 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.26 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,254 | 30 | SANOFI US SERVICES INC. ($2,435) |
| 2023 | $144.87 | 8 | Alexion Pharmaceuticals, Inc. ($35.31) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 11/13/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Neurology | ||||||
| 08/21/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Neurology | ||||||
| 08/01/2024 | Mylan Specialty L.P. | GLATIRAMER ACETATE (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Immunomodulators | ||||||
| 06/05/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Genetic Disease | ||||||
| 05/29/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: Immunology | ||||||
| 05/29/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $65.85 | General |
| Category: Immunology | ||||||
| 05/29/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $60.09 | General |
| Category: Immunology | ||||||
| 05/08/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: NEUROLOGY | ||||||
| 04/18/2024 | Amgen Inc. | ACTIMMUNE (Biological) | Food and Beverage | In-kind items and services | $32.20 | General |
| Category: Bone/Inflammation/Rare Disease | ||||||
| 04/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| 03/20/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: IMMUNOLOGY | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $908.60 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $661.82 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $284.99 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $84.99 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $75.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $34.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $3.68 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/08/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $144.93 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/08/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $84.99 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/08/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $75.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/08/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $34.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $2,435 | 13 |
About Amy Gilbert, CNP
Amy Gilbert, CNP is a Family healthcare provider based in Plymouth, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2023. The National Provider Identifier (NPI) number assigned to this provider is 1780461681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amy Gilbert, CNP has received a total of $4,399 in payments from pharmaceutical and medical device companies, with $4,254 received in 2024. These payments were reported across 38 transactions from 19 companies. The most common payment nature is "" ($2,435).
Ad
Practice Information
- Specialty Family
- Location Plymouth, MN
- Active Since 09/13/2023
- Last Updated 09/13/2023
- Taxonomy Code 363LF0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780461681
Products in Payments
- Ocrevus (Biological) $1,551
- PONVORY (Drug) $36.70
- ACTIMMUNE (Biological) $32.20
- NUEDEXTA (Drug) $31.98
- Haegarda (Biological) $24.20
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $24.04
- HYQVIA (Biological) $23.26
- Albuked (Biological) $20.37
- SOLIRIS (Biological) $19.78
- Rystiggo (Drug) $18.71
- TYSABRI (Biological) $18.53
- GLATIRAMER ACETATE (Drug) $17.80
- BOTOX (Biological) $16.60
- ZEPOSIA (Drug) $15.62
- ULTOMIRIS (Biological) $14.83
- KESIMPTA (Drug) $14.40
- WAINUA (Drug) $14.09
- AMVUTTRA (Drug) $13.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Plymouth
Kyle Farr, Np-C, NP-C
Family — Payments: $200,487
Family $200,487
Mrs. Candie Books, Fnp-C, FNP-C
Family — Payments: $10,392
Family $10,392
Mrs. Brittany Walsh, Fnp, FNP
Family — Payments: $6,026
Family $6,026
Marla Troyer, Fnp, FNP
Family — Payments: $5,916
Family $5,916
Kathleen Brodt, Nurse Practitioner, NURSE PRACTITIONER
Family — Payments: $5,057
Family $5,057
Glenda Ensweiler, Np, NP
Family — Payments: $4,989
Family $4,989